Everything you need to win OPKO Health — in one platform.
Who to reach, what to say, and why now on OPKO Health — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on OPKO Health — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
Jul 17, 2024•almost 2 years ago
Contract Type
agreement
MiamiBiotechnologyHealth CareBiopharma
Description
OPKO Health has entered into a $250 million note purchase agreement with HealthCare Royalty, secured by OPKO’s profit share payments from Pfizer related to NGENLA™, a once-weekly treatment for pediatric growth hormone deficiency. This agreement allows OPKO to retain a significant portion of NGENLA's profit share payments in the near term, provides non-dilutive capital, and financial flexibility for research and development activities.
Company Information
Company
OPKO Health
Location
Miami, Florida, United States
About
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.
MiamiBiotechnologyHealth CareBiopharma